NCT02366130 - Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 11, 2015

Primary Completion Date

December 16, 2020

Study Completion Date

December 16, 2020

Conditions

Breast Cancer

Interventions

DRUG

Ra-223 dichloride

55 kBq/kg by vein on Day 1 of each 28 day cycle, and then every four weeks thereafter for 6 cycles.

DRUG

Denosumab

120 mg by subcutaneous (SC) injections on Day 1 of Cycles 2-5.

DRUG

Hormone Therapy

A single hormonal agent administered daily while on study. Physician to decide what type of hormone therapy participant will receive.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston